Kornimate/medical-research-clean huggingface dataset:
clinical intervention on cognitive impairment of schizophrenia with metabolic syndrome

Conditions: Schizophrenia

Summary: this is a single-center, randomized, parallel-control study conducted in schizophrenic inpatients with metabolic syndrome who have been conducted with olanzapine. the purpose of this study is to evaluate the efficacy and safety of omega-3 polyunsaturated fatty acids, xbox aerobic exercise and transcranial direct current stimulation( tdcs). following a screening period, subjects who meet the entry criteria will be randomized to treated with omega-3 polyunsaturated fatty acids1.2mg per day, xbox aerobic exercise 30min per day and tdcs at 2ma, 20 min(5 session/week) for 12 weeks.


Eligibility criteria:
inclusion criteria: 1. meets the diagnostic and statistical manual of mental disorder,fifth edition(dsm-v) criteria for schizophrenia. 2. patients have got standard treatment of olanzapine monotherapy for more than 6 months, panss baseline ≤ 60. 3. meets the atp-iii criteria for metabolic syndrome. 4. male or female subjects aged 18-60 years, education level of junior high school for above. 5. the patient fully understand and signed the informed consent form. exclusion criteria: 1. serious and instable body disease such as cerebrovascular disease, liver and kidney disease, disease of internal secretion (abnormal thyroid function), blood disease; any history of seizures or other organic brain diseases. 2. pregnant or lactating women and women of childbearing potential throughout the study period; patients who have plans to move to other places within the year. 3. history of diabetes, hyperlipidemia and other metabolic abnormalities. 4. due to other reasons, the researchers considered it unsuitable to participate in this clinical trial. -
observational research on use of immunoprop supplement in chronic fatigue syndrome

Conditions: Chronic Fatigue Syndrome

Summary: observational study regarding the use of supplements in chronic fatigue syndrome patients

detailed questionnaire regarding the diagnosis of an onset of chronic fatigue syndrome and 100 patients. using karnofsky scale before and after use of supplements patient scores are compared in a double blind trial.

Eligibility criteria:
inclusion criteria: * fukuda criteria and canadian consensus criteria will be the diagnosis criteria for patient selection exclusion criteria: * non inclusion in the above criteria

Keywords: chronic fatigue syndrome karnofsky score supplements
measuring evoked potentials from the spinal cord and dorsal root ganglion

Conditions: Neuropathic Pain

Summary: the purpose of this study is to determine the feasibility of recording evoked compound action potentials (ecaps) and somatosensory evoked potentials (sseps) from the spinal cord (sc) and dorsal root ganglions (drg), and their suitability as feedback signals.


Eligibility criteria:
inclusion criteria: * subject is at least 18 years of age. * subject is able and willing to comply with the schedule and protocol. for implantation of drg stimulator; * subject has been diagnosed with complex regional pain syndrome (crps i or ii). * subject has had chronic, intractable pain of the groin or lower limbs for at least 6 months. * subject is indicated for implantation of an abbott drg stimulation system. * subject will be undergoing trial implantation of an abbott drg stimulation system. for implantation of scs; * subject has been diagnosed with chronic, intractable pain of the trunk and/or limbs. * subject is indicated for implantation of a scs system. * subject will be undergoing implantation of an abbott lead. * subject has had stable neurologic function in the past 30 days. * subject is able to provide informed consent. exclusion criteria: * subject will be implanted with 3 or more drg leads. * subject is currently participating in a clinical investigation that includes an active treatment arm. * subject has exhibited escalating or changing pain condition within the past 30 days as evidenced by physician examination. * subject currently has an active implantable device including an icd, pacemaker, spinal cord stimulator, or intrathecal drug pump. * subject is a prisoner. * female subject is pregnant.
a study to evaluate the safety and efficacy of msenc1 soft hydrophilic contact lenses and oxypure color soft hydrophilic contact lenses

Conditions: Myopia

Summary: this project is an open, parallel, randomly controlled, and non-inferiority clinical trial of msenci soft hydrophilic contact lenses with oxypure color soft hydrophilic contact lenses used as the control product.


Eligibility criteria:
inclusion criteria: 1. age ≥ 18 years old, no gender limitation; 2. soft hydrophilic contact lenses worn should be from 0.00d to -12.00d; 3. subjects should have normal binocular conditions without any abnormality or diseases except for ametropia; 4. the optimal binocular cva with glasses ≥ 1.0; 5. the astigmatism should be ≤1.5d; 6. binoculus but \&gt;5s; 7. should accept follow-ups for at least 90 days and wear the contact lens as required in the protocol; 8. should understand the purpose of the trial, volunteer to attend and sign the informed consent form by the subjects themselves or their legal guardians. . exclusion criteria: 1. patients who suffer from systemic diseases that prohibit contact lens use or receive treatment that may affect the vision or contact lens use; 2. patients who have worn hard contact lenses within 4 weeks or soft contact lenses within 7 days before being included in the trial; 3. patients who are allergic to contact lenses or suffer from systemic allergy; 4. patients who have keratoconus or other cornea irregularity; 5. patients who always stay at places that are dry, dust-heavy, having volatile chemicals or otherwise affect the use of soft hydrophilic contact lenses; 6. people who are pregnant, during their lactation or prepare for the pregnancy while being included; 7. people who have only a single eye qualified for the trial; 8. people who have attended a clinical trial of medicine or medical devices other than contact lens within 3 months before being included in this trial; 9. people who have attended a clinical trial of medicine or medical devices other than contact lens within 3 months before being included in this trial; 10. other cases where investigators determine the soft contact lens should not be used or the candidate should be excluded.
study to evaluate the pharmacokinetics, safety, and tolerability of bms-708163

Conditions: Alzheimer's Disease

Summary: the purpose of the study is to evaluate the pharmacokinetics, safety and tolerability of bms-708163 administered as single and multiple doses in chinese subjects


Eligibility criteria:
inclusion criteria: * healthy male subjects 18-45 yrs old and 65 yrs or older inclusive and postmenopausal female 65 yrs or older exclusion criteria: * women of childbearing potential * gastrointestinal disorders * bleeding disorders * peptic ulcer disease * abnormal ecg * abnormal clinical laboratory tests * abnormal thyroid * congestive heart failure * cholecystectomy * asthma * hypertension * inability to tolerate oral medication * inability to be venipunctured and/or tolerate venous access
a dose escalation study of intranasal neuropeptide y in post traumatic stress disorder (ptsd)

Conditions: Posttraumatic Stress Disorder

Summary: this study is designed to investigate the safety of intranasal administration of npy using a dose escalation, randomized, double-blinded, placebo-controlled crossover design in a medication-free, symptomatic ptsd group.


Eligibility criteria:
inclusion criteria: * men and women, age 18-60. * participants must have a level of understanding sufficient to agree to all tests and examinations required by the protocol and must sign a written informed consent document. we determine whether they have a sufficient understanding of the study procedures and risks by asking them to explain what's involved in the study and to give examples of study risks and benefits. * participants must fulfill dsm-iv criteria for current ptsd, based on the structured clinical interview for dsm-iv axis i disorders (scid-i) and on the clinician-administered ptsd scale (caps). * caps score must be at least 40 (moderate ptsd severity) at screening. exclusion criteria: * current, primary axis i disorders other than ptsd. * history or current bipolar disorder or primary psychotic disorders (e.g. schizophrenia, schizoaffective disorder). * current diagnosis of anorexia nervosa or bulimia nervosa. * women who are pregnant or are breast-feeding. * drug or alcohol abuse or dependence within the preceding 3 months. * poorly controlled hypertension (manifest by sbp \> 140 and/or dbp \> 90); hr \ 100 at rest at the time of screening and confirmed immediately prior to randomization * evidence of coronary artery disease as evidenced by history, abnormal ecg, typical symptoms * history of arrhythmia, cardiac surgery, or family history of sudden death * hepatic dysfunction as defined by ast and alt \> 2x url, or alkaline phosphatase and bilirubin \> 1.5 x url within x days prior to randomization * chronic renal disease as defined by serum creatinine \> 1.9 * any other serious or unstable clinically significant abnormal findings of laboratory parameters, physical examination, or ecg as determined by the pi. * any other serious or unstable condition that would put the subjects at undue risk as determined by the pi or additional safety monitor. * serious and imminent suicidal or homicidal risk. * psychotropic medication that will not be tapered off at least 7 days prior to screening; withdrawal symptoms must be absent at the time of screening * history of nasal disorders or sinonasal surgery, or significant nasal abnormalities based on nasal exam. * received investigational intervention within 30 days prior to randomization

Keywords: neuropeptide y intranasal administration ptsd trauma
assessment of intranasal steroids in allergic rhinitis when used alone or in combination with an oral antihistamine (study p03270)

Conditions: Rhinitis, Allergic

Summary: this is a phase 4, non-comparative, open-label, multi-center study. it is designed to determine the effectiveness of regular intranasal steroid use in alleviating allergic rhinitis nasal symptoms, when used alone or in combination with an oral antihistamine. subjects will receive 200 mcg (2 puffs in each nostril) of mometasone furoate once a day. an oral antihistamine at the discretion of the physician may be added at day 28 (visit 2), if patients fail to improve nasal symptoms.


Eligibility criteria:
inclusion criteria: * subjects must demonstrate their willingness to participate in the study and comply with its procedures by signing a written informed consent form * subjects must be between 18-65 years of age, of either sex and any race * subjects must be diagnosed by the physician to have moderate to severe allergic rhinitis according to aria guidelines. * subjects must be mometasone furoate naïve. exclusion criteria: * significant comorbid medical condition. * respiratory tract infection. * any contraindications according to mometasone furoate product monograph. * patients who have received antihistamine treatment within the last 5 days. * patients who have received corticosteroid treatment within the last 30 days. * patients who are likely to require the administration of systemic steroids during the course of this program. * any condition which in the doctor's opinion could interfere with the patient completion of this program. * pregnant or lactating patients. * patients with local infections involving the nasal mucosa. * patients with structural abnormalities or who have undergone nasal surgery or trauma in the past 6 months. * patients with hypersensitivity to mometasone furoate or are allergic to corticosteroids. * patients who are prone to nose bleeding.
efficacy of folrex in the superior extremity rehabilitation after acute stroke

Conditions: Stroke

Summary: the purpose of the study is to evaluate whether folrex, could improve the motor recovery of the upper extremity after stroke in comparison with placebo during 4 weeks of treatment.

periodical measures of the motor recovery, of the upper extremity, by fugl-meyer score, it will be done at the beginning, at fifth day and at month. each value will be compare to evaluate whether the groups of patient improve.

Eligibility criteria:
inclusion criteria: * patients with acute stroke \< 24 hours. * patients with impairment up to 4 on nihss scale. * family support. * informed consent. exclusion criteria: * presence of another disease not well controlled. * patient with dementia.
a4b7 integrin in eosinophilic esophagitis

Conditions: Eosinophilic Esophagitis

Summary: the overall objective of this preclinical study is to further the investigators mechanistic understanding of the role that the α4β7 and mucosal addressin cell adhesion molecule (madcam-1) pathway plays in mediating eosinophil recruitment in eoe. to accomplish this, the investigators aim to (1) determine the baseline and dynamic patterns of α4β7 integrin expression on circulating and tissue eosinophils in eoe and in the setting of non-eoe esophageal eosinophilia (e.g., reflux esophagitis) and (2) determine the complete profile of eosinophil integrin molecules that may play a role in active eoe.


Eligibility criteria:
inclusion criteria: 1. able to give written informed consent 2. male or female patients aged 18-65 years at time of screening 3. confirmed active eoe at screening or within 8 weeks prior to baseline visit, as defined by esophageal mucosal eosinophils ≥15 per high power field (hpf, 400x magnification) despite at least 4 weeks of proton pump inhibitor (ppi) therapy with omeprazole 20 mg twice daily or the equivalent. updated 14apr2015 page 8 of 19 4. within the week prior to dosing, patient has one of the following symptoms of moderate, or worse, severity: dysphagia, vomiting, regurgitation, abdominal pain, chest pain/heartburn. 5. maintained on a stabilized diet for at least 6 weeks prior to screening and during the course of the study; stable diet is defined as no initiation of single or multiple elimination diets or reintroduction of previously eliminated food groups. 6. willing and able to comply with all clinic visits and study-related procedures 7. able to understand and complete study-related questionnaires exclusion criteria: 1. another disorder that causes esophageal eosinophilia (e.g., hypereosinophilic syndrome, churg-strauss, parasitic infection) 2. history of abnormal gastric or duodenal biopsy or documented gi disorders other than eoe (e.g., celiac disease, crohn's disease or h. pylori infection) 3. history of the following gi surgeries: fundoplication, gastric surgery or surgery for esophageal atresia 4. use of systemic immunosuppressive or immunomodulating agents (oral prednisone, anti-immunoglobulin e (ige) monoclonal antibody (mab), methotrexate, cyclosporine, infα, or anti-tnf) within six months prior to study entry. 5. a stricture on endoscopy that prevents passage of the endoscope 6. participation in any investigational drug or device study within 30 days prior to study entry. 7. female subjects who are pregnant or nursing. 8. chronic infections such as hiv, hepatitis b or c, active mycobacterial (tb) or fungal infections. 9. neoplasm or a history of malignancy in the preceding 5 years. 10. concurrent infection or disease that may preclude assessment of eosinophilic esophagitis.

Keywords: eosinophilic esophagitis eoe integrins
post transjugular intrahepatic portosystemic shunt (tips) albumine infusion to prevent hepatic encephalopathy

Conditions: Hepatic Encephalopathy

Summary: the purpose of this study is to evaluate the efficacy of albumin infusion to prevent post tips hepatic encephalopathy'

the outcome is the prevention of post tips hepatic encephalopathy

Eligibility criteria:
inclusion criteria: * cirrhotic patients * tips placement * absence of hepatic encephalopathy at the enrolement * age \> 18 years * no pregnancy exclusion criteria: * non-cirrhotic portal hypertension * previous liver transplantation * impossibility to attend the scheduled follow-up including the weekly visit as outpatients during the first month after tips (see the description of follow-up below) * sings of overt hepatic encephalopathy as well as a history of persistent he at entry. the latter as a contraindication for tips placement

Keywords: tips albumin hepatic encephalopathy hyponatremia hypovolemia cirrhosis
quality of sexual function in brca mutated women

Conditions: BRCA Mutation; Sexual Dysfunction; Sexual Dysfunctions, Psychological; Sexual Dysfunction, Physiological

Summary: quality of sexual function in brca mutated women is investigated using sfq28 questionnaire.

we aim to investigate and compare the impact of diagnosis of brca, the impact of risk reducing surgery (rrs) and oncological diagnosis.

Eligibility criteria:
inclusion criteria: * tbc exclusion criteria: * tbc

Keywords: brca sexual
use repetitive transcranial magnetic stimulation to treat somatic symptom disorder

Conditions: Somatic Symptom Disorder

Summary: this is a randomized double-blind sham-controlled crossover study; the interventions are high-frequency rtms stimulation on left dlpfc and sham control. the study population is the patient with somatic symptom disorder. the primary outcomes are somatic distress and health anxiety.

somatic symptom disorder (ssd) is a psychiatric diagnosis featured with somatic distress and health anxiety. it is overlapped with functional disorders. whether it has effective treatment is a clinically important issue. current evidence indicates that pharmacotherapy and psychotherapy are both helpful for ssd. among other treatment options, repetitive transcranial magnetic stimulation (rtms) is attached important in psychiatric field; it can cause activation or inhibition of specific brain regions via magnetic stimulation. previous studies have disclosed that rtms is helpful for depression, obsessive-compulsive disorder, post-stroke rehabilitation, etc. regarding functional disorders, fibromyalgia has been found to be benefited from rtms; the effective approaches include giving high-frequency stimulation on left m1 and dorsolateral prefrontal cortex (dlpfc). chronic tinnitus was also found to have response to rtms. ssd and fibromyalgia are highly overlapped; ssd and depression are often comorbid. therefore, ssd may also be benefited from left dlpfc high-frequency stimulation. our previous study revealed that dysfunction of anterior cingulate cortex (acc) is associated with persistent interference of the somatic discomforts; stimulation on dlpfc can cause acc activation. this study program was designed based on the above information. it is a randomized double-blind sham-controlled crossover study; the interventions are high-frequency rtms stimulation on left dlpfc and sham control. the primary outcomes are somatic distress and health anxiety. there is not study about rtms on ssd in literature; the investigators expect this study to be able to provide more understanding on this field.

Eligibility criteria:
inclusion criteria: * patient with somatic symptom disorder (confirmed by psychiatrists) * age 20-70 exclusion criteria: * having psychotic symptoms or cognitive impairment * having potentially lethal illness * using cardiac pacemakers or defibrillators * currently pregnant or having plans to become pregnant within the next three months * received rtms treatment within three months * cannot read the questionnaires by oneself * having to take the following medications persistently: bupropion \>300 mg/day、tca、clozapine、chlorpromazine、foscarnet、ganciclovir、ritonavir、theophylline

Keywords: somatic symptom disorder repetitive transcranial magnetic stimulation dorsolateral prefrontal cortex somatic distress health anxiety
peking and rotterdam on mission to reduce coronary artery disease

Conditions: Acute Coronary Syndrome; Diabetes Mellitus

Summary: the purpose of this study is to explore the effect of 20mg high loading dose of rosuvastatin on recurrent events in patients with established dm who is admitted for an acs.


Eligibility criteria:
inclusion criteria: * • men or women ≥40 years of age admitted with a clinical diagnosis of acs. the diagnosis should be based on the combination of typical ischemic chest complaints and objective evidence of myocardial ischemia or myocardial necrosis as demonstrated by the electrocardiogram (ecg) or elevated cardiac markers, as follows: * typical ischemic chest pain, lasting 10 minutes or more, within the preceding 24 hours, and either * ecg changes indicative of myocardial ischemia within 24 hours after the onset of chest pain (ecg showing persistent or non-persistent st-segment elevation \>1.0 mm in two or more contiguous leads or dynamic st-segment depression \>1.0 mm in two or more contiguous leads) or * elevated biomarkers of myocardial necrosis within 24 hours after the onset of chest pain (i.e. ck-mb \>1 times the upper limit of normal of the local laboratory, or troponin-t \>0.1 ng/ml. * a diagnosis of dm type ii prior to the index acs * written informed consent exclusion criteria: * • myocardial ischemia precipitated by a condition other than atherosclerotic coronary artery disease (e.g. arrhythmia, severe anemia, hypoxia, thyrotoxicosis, cocaine, severe valvular disease, hypotension). * severely-impaired left ventricular function (ejection fraction \<30%) or end-stage congestive heart failure nyha-class iii or iv (in order to avoid lost-to-follow-up due to non-acute coronary syndrome events). * severe chronic kidney disease with measured or calculated glomerular filtration rate (cockgroft-gault or mdrd4 (modification of diet in renal disease) formula) of \<30 ml/min/1.73m2, or renal dialysis. * co-existent condition associated with a life-expectancy \<12 months, or otherwise unlikely to appear at all scheduled follow-up visits. * known serious or hypersensitivity reactions to hmg-coa reductase inhibitors. * triglyceride (tg) level ≥500 mg/dl (5.65 mmol/l) at screening, because patients with very high triglyceride levels warrant treatment with agents that may increase the risk of side effects associated with statin drugs. * active liver disease or hepatic dysfunction, as determined by alanine aminotransferase (alt \[sgpt\]) \>3 x uln or bilirubin levels \>1.5 x uln at screening. * myopathy. * not using effective contraceptive methods. * participation in any investigational drug study less than 30 days prior to enrolment.

Keywords: acute coronary syndrome diabetes mellitus statins high loading dose recurrent events